Shares of Summit Therapeutics SMMT rose more than 15% on Friday after the analysts at Cantor Fitzgerald and Truist Securities ...

Summit Therapeutics Inc.’s SMMT share price has surged by 5.60%, which has investors questioning if this is right time to sell.

Shares of lung cancer-focused biotech Summit Therapeutics ( SMMT 10.72%) rallied 16.6% at its highs of the day before ...

Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other ...

However, sell-offs present great opportunities to buy stocks with significant upside potential. Further, CRISPR Therapeutics ...

Summit Therapeutics (NasdaqGM:SMMT) recently experienced an executive shakeup with the appointment of Robert LaCaze as Chief Commercial Officer, which could have influenced its stock price increase of ...

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, announced that Randall ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today. The company’s ...

In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other biotech stocks that dominate Monday’s top gainers. The stock market kicked off ...

Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.